Bristol-Myers Squibb

EU regulators reject new use for Opdivo, as Keytruda edges ahead

https://pharmaphorum.com/news/eu-regulators-reject-new-use-for-opdivo-as-keytruda-edges-ahead/

BMS immunotherapy combo approved in new colorectal use

https://pharmaphorum.com/news/bms-immunotherapy-combo-approved-in-new-colorectal-use/

NICE rejects BMS immunotherapy in advanced bladder cancer

https://pharmaphorum.com/news/nice-rejects-opdivo-in-advanced-bladder-cancer/

Roche to file Tecentriq in triple negative breast cancer

https://pharmaphorum.com/news/roche-files-tecentriq-triple-negative-breast-cancer/

EU regulators back BMS’ Opdivo in new skin cancer use

https://pharmaphorum.com/news/eu-regulators-back-bms-opdivo-in-new-skin-cancer-use/

ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O

https://pharmaphorum.com/event-coverage/asco-2018-bms-merck-co-locks-out-lung-cancer-i-o/

ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more

https://pharmaphorum.com/views-analysis-oncology/asco_2018-opdivo-nektar-abbvies-leukaemia/

Merck & Co’s Keytruda could catch BMS’ rival with new lung cancer use

https://pharmaphorum.com/news/merck-keytruda-bms-opdivo-lung-cancer-use/

EU approves Ipsen’s Cabometyx in first line kidney cancer

https://pharmaphorum.com/news/eu-approves-ipsens-cabometyx-in-first-line-kidney-cancer/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search